No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because the lot number was provided by the customer.Concomitant products used in this study: carto, thermocool smarttouch, thermocool smarttouch sf.Non-biosense webster devices that were also used in this study: none.Manufacturer's ref.No: (b)(4).Biosense webster manufacturer's report numbers: 2029046-2018-02353; 2029046-2018-02354; 2029046-2018-02355.Are related to the same incident.
|
This complaint is from a literature source.The following complications were reported in this publication: 1 patient underwent catheter ablation of focal ventricular arrhythmia in the setting of cardiomyopathy suffered femoral pseudoaneurism, requiring thrombin injection.No further details were provided.Multiple requests for clarification have been sent to the corresponding author, but no additional details were provided at this time.If additional details will be provided this report will be updated accordingly.There are 0 death events and 0 device malfunctions reported in this publication.Model and catalog number are not available, but the suspected device is thermocool.Other biosense webster devices that were also used in this study: carto, thermocool smarttouch, thermocool smarttouch sf.Non-biosense webster devices that were also used in this study: none.Publication details: title: ventricular ectopy in the context of left ventricular systolic dysfunction: risk factors and outcomes following catheter ablation.Objective: to assess medium term outcomes of focal ventricular arrhythmia (va) ablation in the setting of cardiomyopathy (cmp) and to validate published risk factors for ectopy-mediated cardio myopathy (emc).Methods: medium term recovery of left ventricular (lv) function and freedom from va recurrence was assessed and compared between patients undergoing focal va ablation in the setting of cmp (n = 53) and a control group with normal lv function (n = 98) between 2011 and 2017.Total = 152 patients.
|